Congenital hypogonadotropic hypogonadism/Kallmann Syndrome is associated with statural gain in both men and women: a monocentric study.
Congenital hypogonadotropic hypogonadism/Kallmann Syndrome (CHH/KS) is a rare condition characterized by gonadotropin deficiency and pubertal failure. Adult height (AH) in patients with CHH/KS has not been well studied. To assess AH in a large cohort of patients with CHH/KS. A total of 219 patients (165 males, 54 females). Parents and siblings were included. AH was assessed in patients and family members. AH was compared to the general French population, parental target height (TH) and between patients and same-sex siblings. Delta height (∆H) was considered the difference between AH and parental TH. ∆H was compared between patients and siblings, normosmic CHH and KS (CHH+anosmia or hyposmia), and according to underlying genetic defect. We examined correlations between ∆H and age at diagnosis and therapeutically-induced individual statural gain. Mean AH in men and women with CHH/KS was greater than in the French general population. Patients of both sexes had statural gain (AH>TH). Males with CHH/KS were significantly, albeit moderately, taller than their brothers. ∆H was higher in CHH/KS compared to unaffected siblings (+6.2±7.2 cm versus +3.4±5.2 cm, p<0.0001). ∆H was positively correlated with age at diagnosis (r=0.22, p=0.002). Neither olfactory function (normosmic CHH vs KS) nor specific genetic cause impacted ∆H. Individual therapeutically induced growth gain inversely correlated with the age at initiation of hormonal treatment (r=-0.57, p<0.0001). Patients starting treatment prior to age 16 gained more height with therapy compared to delayed treatment (16.6±5.9 versus 4.1±5.2 cm, p<0.0001). CHH/KS is associated with a significant statural gain compared to the general population, mid-parental TH and same sex siblings. Greater height in CHH/KS than siblings indicates that those differences are independent of an intergenerational effect on statural gain.